Scope, Claims, and US Patent Landscape for US Patent 8,637,512 (Lamotrigine Sustained-Release Matrix with pH-Triggered, Orificed, Eudragit L30 D55 Outer Coat)
US 8,637,512 claims a lamotrigine sustained-release (SR) oral dosage form defined by (i) a two-phase release behavior tied to GI pH (slower in esophagus/stomach, faster when pH exceeds 5) and (ii) a tablet architecture: matrix core plus an outer pH-dissolving methacrylic copolymer coat (Eudragit L30 D55) that is substantially impermeable until pH > 5, with orifices through the coat that gate the release predominantly through the openings. The independent claim is operationally narrow because it recites specific excipient classes, specific polymer brands/grades, an outer-coat thickness window, and a quantitative orifice-face-area fraction.
What exactly does the claim language bind (independent claim 1)?
What is the claimed product structure and how is it expected to release?
Claim 1 requires all of the following elements:
-
Dosage form type and release pattern
- A sustained release formulation of lamotrigine with a mean serum concentration-time profile “shown in or substantially similar to” the second graph of FIG. 8.
- A matrix tablet having two phases of lamotrigine release:
- First phase: release rate occurs in the oesophagus and stomach, and is slower.
- Second phase: release rate occurs when surrounding pH exceeds 5, and is faster than phase 1.
-
Core composition (matrix)
- Core comprises:
- (a) 2.5% to 80% by weight lamotrigine
- (b) 17.5% to 70% by weight release-retarding hydroxypropylmethylcellulose (HPMC) polymer, comprising:
- Methocel E4M and Methocel K100LV
- (c) 0% to 60% by weight diluent
- (d) 0% to 20% by weight compression aid
- (e) 0.1% to 2.5% by weight lubricants
-
Outer coat composition and pH dissolution gating
- Outer coat covering the core comprises:
- (f) 0.05 mm to 0.30 mm of methacrylic copolymer Eudragit L30 D55
- Coat functional limitations:
- Substantially impermeable to environmental fluid entrance
- Substantially impermeable to lamotrigine exit
- Dissolves when surrounding pH exceeds 5
-
Orifices through the coat that control release location
- Coat includes one or more orifices:
- extend from outside of the coating
- pass substantially completely through the coat
- do not penetrate the core
- Orifice sizing limitation:
- area or combined area from 10% to 60% of face area of the formulation
- Release is required to occur substantially through said orifice.
What are the strongest narrowing features for infringement?
Claim 1 is most difficult to design around because it combines multiple “orthogonal” constraints that must all be met:
- Brand/grade-specific polymer identity in the core:
- HPMC must comprise Methocel E4M and Methocel K100LV (not merely “HPMC” generally).
- Outer polymer identity:
- Must be Eudragit L30 D55.
- Outer coat thickness:
- Orifice geometry (location + size fraction):
- Orifices go through the coat but not into the core.
- Orifice-face-area fraction 10% to 60%.
- Functional permeability language:
- coat is “substantially impermeable” pre-pH>5 (both fluid entrance and drug exit).
- Release behavior tied to pH > 5:
- first phase in esophagus/stomach slower; second phase pH>5 faster.
- FIG. 8 concentration-time profile mapping:
- “shown in or substantially similar” to the second graph of FIG. 8.
Those features collectively define a specific mechanistic release architecture: coat delays water ingress/drug egress until pH triggers dissolution; then release focuses through discrete openings.
How much narrower is claim 2 (PK performance overlay)?
What additional PK metrics does claim 2 impose?
Claim 2 depends on claim 1 and adds in vivo performance requirements on administration to humans:
- AUC must be within 80% to 125% of a comparator.
- Cmax must be about 30% less than an instant release tablet containing the same amount of lamotrigine.
Claim 2 therefore requires not only the structural elements of claim 1, but also a specific systemic exposure and peak suppression profile relative to an instant-release reference.
Scope mapping: what does the claim cover and what does it exclude?
What does claim 1 likely cover (within its literal bounds)?
Within literal parameters, claim 1 covers a fairly broad range of formulations as long as they still maintain the claimed architecture and release behavior:
- Lamotrigine loading: 2.5% to 80% by weight in the core.
- HPMC retarder system: between 17.5% and 70% by weight total HPMC comprised of Methocel E4M + Methocel K100LV (either or both present as part of the blend).
- Diluent/compression aid/lubricant tolerance:
- diluent can be 0% to 60%
- compression aid can be 0% to 20%
- lubricant can be 0.1% to 2.5%
- Coating design space:
- Eudragit L30 D55 coat thickness 0.05 to 0.30 mm
- orifice area fraction 10% to 60%
- orifices that reach through the coat but not into core
What does claim 1 likely exclude (by requiring exact elements)?
Claim 1 would likely exclude variants that change any of the following:
- Substitution away from Eudragit L30 D55 as the outer-coat polymer.
- Use of an outer coat that does not become dissolving at pH > 5 (or does not maintain “substantially impermeable” behavior before that).
- Orifices that penetrate into the core, or orifices that do not extend “substantially completely” through the coating.
- Orifice-face-area fraction outside 10% to 60%.
- Use of an HPMC retarder system that does not include Methocel E4M and Methocel K100LV.
- Release profiles that are not “substantially similar” to the FIG. 8 second graph (practical enforcement will hinge on the factual expert record, but the claim language itself is still a binding reference point).
Claim construction pressure points (where disputes tend to form)
What terms are most likely to drive claim-construction and infringement/validity fights?
These are the claim elements that typically force expert testing, process scrutiny, and reference-to-specification work:
-
“Substantially impermeable”
- The claim couples impermeability to both fluid entrance and lamotrigine exit pre-pH>5.
-
“Substantially similar” to FIG. 8
- This is inherently comparative and usually becomes a matter of what test conditions, tolerances, and statistical similarity are argued.
-
Orifices “substantially completely through said coating but not penetrating said core”
- Tablet cross-section measurements and manufacturing control become central.
-
Orifice area fraction “about 10 to about 60 percent of the face area”
- Boundary cases (near 10% or 60%) are fertile for non-infringement arguments.
-
Two-phase release tied to esophagus/stomach vs pH>5
- The claim ties phase assignment to physiologic regions and to pH > 5; actual release in GI simulation may vary.
-
Cmax and AUC ranges in claim 2
- Exposure metric selection, reference formulation identity, and statistical window can matter (claim language ties AUC range to a comparator but does not state the exact AUC definition method).
Practical infringement logic: how a competitor would map its product against claim 1 and claim 2
What must be proven for claim 1?
To capture claim 1, the accused product should have:
- Lamotrigine SR matrix with core + outer coat architecture
- Core:
- 2.5% to 80% lamotrigine
- 17.5% to 70% HPMC retarder blend including Methocel E4M and Methocel K100LV
- Outer coat:
- Eudragit L30 D55
- thickness 0.05 to 0.30 mm
- dissolves at pH > 5
- is substantially impermeable to fluid ingress and lamotrigine egress pre-dissolution
- Orifices:
- go through coat, not into core
- total orifice area is 10% to 60% of face area
- release occurs substantially through orifice
- Release behavior:
- two phases consistent with slower esophagus/stomach release and faster pH>5 phase
- PK profile similar to FIG. 8 second graph
What must be added for claim 2?
On top of claim 1 structure, claim 2 requires:
- Human AUC between 80% and 125%
- Human Cmax about 30% less vs instant release tablet of same dose.
Patent landscape assessment (US-focused) based on the claim’s identifiable “technical core”
You provided only the asserted claims, not bibliographic details (filing date, priority, family, assignee) or the patent document’s full specifications. Without those, a complete forward/backward citation network and expiry/patent-term map cannot be produced accurately. What can be stated from the claim text alone is the technical “landscape cluster” the patent sits in:
What technology bucket is this patent in?
This patent sits in the intersection of:
- pH-triggered methacrylic copolymer-coated tablets (Eudragit L30 D55, dissolution above pH 5)
- Orificed or controlled-permeation dosage forms where openings gate drug release
- HPMC matrix sustained release using specific Methocel grades
How would nearby patents typically differ?
Competitors typically attempt to avoid this claim by changing one of these three axes:
- Outer coat polymer or thickness window
- Orifice concept (size, placement, or whether openings penetrate to core)
- Core retarder system (substituting HPMC grades or retarder type)
Given the brand/grade recitations, a common design-around would be to use a different HPMC grade set than Methocel E4M + Methocel K100LV or to use a different methacrylic copolymer than Eudragit L30 D55. Another design-around would be to change the coating thickness or the orifice-face-area fraction outside 10% to 60%.
Where the landscape can compress or widen
- Compression: Many products may share “Eudragit L30 D55 + pH >5 dissolution” logic, but fewer will combine the exact core HPMC grade blend and the specific orifice-face-area fraction and “not penetrating core” architecture.
- Widening: If other patents use pH-triggered coatings without orifices (or with orifices that penetrate into core), they likely fall outside claim 1 despite similar overall “delayed then release” behavior.
What business decisions should be made from this claim scope?
How strong is this claim set as a platform patent?
As written, claim 1 is a platform-like formulation claim because it uses broad numeric ranges for lamotrigine loading, diluent, compression aid, and lubricant, while reserving critical narrowing specificity to:
- specific HPMC grades
- specific outer coat polymer
- outer coat thickness range
- orifice placement and orifice face area fraction
- pH-triggered two-phase release and FIG. 8 similarity
That structure tends to support enforcement against products that keep the same mechanistic architecture, while allowing freedom to reformulate “non-critical” components (diluent, compression aid, some lubricant level) without leaving the literal scope.
Where to focus due diligence
For any freedom-to-operate or infringement risk assessment, the highest-yield evidence to collect is:
- composition confirmation of HPMC grades in the core
- identity and thickness of Eudragit L30 D55 coat
- tablet cross-sections verifying orifices through coat but not into core
- measurement of total orifice area fraction vs face area
- release and human PK tests to compare to FIG. 8 and the claim 2 AUC/Cmax thresholds
Key Takeaways
- Claim 1 defines a lamotrigine SR tablet with a HPMC matrix core (Methocel E4M + K100LV at 17.5% to 70%) and a pH>5 dissolving outer coat of Eudragit L30 D55 (0.05 mm to 0.30 mm) that is substantially impermeable until pH exceeds 5.
- The outer coat contains orifices through the coat but not the core, with total orifice area 10% to 60% of face area, and release is required to occur substantially through the orifice.
- Two-phase release is tied to slower release in oesophagus/stomach and faster release when pH exceeds 5, with a mean serum profile “substantially similar” to FIG. 8, second graph.
- Claim 2 adds human PK guardrails: AUC 80% to 125% and Cmax about 30% lower versus an instant-release comparator.
- The claim’s enforcement leverage is driven by its brand/grade polymer recitations and quantitative structural gating parameters (coat thickness and orifice-face-area fraction).
FAQs
1) Does claim 1 require Eudragit L30 D55 specifically, or would other pH 5 methacrylates work?
Claim 1 requires the outer coat comprises methacrylic copolymer Eudragit L30 D55 within the 0.05 mm to 0.30 mm thickness range, with dissolution at pH > 5 and pre-dissolution impermeability.
2) Are orifices optional or mandatory in claim 1?
They are mandatory. Claim 1 requires one or more orifices extending through the coat but not penetrating the core, with total orifice area 10% to 60% of face area, and release substantially through the orifice.
3) What HPMC is permitted in the core?
The core retarding polymer must be hydroxypropylmethylcellulose comprising Methocel E4M and Methocel K100LV in an amount of 17.5% to 70% by weight of the core.
4) What does claim 2 protect beyond claim 1?
Claim 2 protects formulations that meet human systemic exposure criteria: AUC 80% to 125% and Cmax about 30% less relative to an instant release tablet containing the same lamotrigine amount.
5) How is the two-phase release defined?
The first phase is in the oesophagus and stomach and is slower; the second phase occurs when the surrounding pH exceeds 5 and is faster.
References (APA)
[1] User-provided text: Claims of U.S. Patent 8,637,512 (lamotrigine sustained-release formulation with Eudragit L30 D55 orificed outer coat and Methocel E4M/K100LV HPMC matrix).
